Article
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity.
Nature communications - 15 Sept 2020
Manzella Gabriele, Schreck Leonie D, Breunis Willemijn B, Molenaar Jan, Merks Hans, Barr Frederic G, Sun Wenyue, Römmele Michaela, Zhang Luduo, Tchinda Joelle, Ngo Quy A, Bode Peter, Delattre Olivier, Surdez Didier, Rekhi Bharat, Niggli Felix K, Schäfer Beat W, Wachtel Marco
Abstract excerpt
Cancer therapy is currently shifting from broadly used cytotoxic drugs to patient-specific precision therapies. Druggable driver oncogenes, identified by molecular analyses, are present in only a subset of patients. Functional profiling of primary tumor cells could circumvent these limitations, but suitable platforms are unavailable for most cancer entities. Here, we describe an in vitro drug profiling platform...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.